Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Fimasartan and Atorvastatin/Ezetimibe in Healthy Volunteers
NCT05372380Phase 1Completed
- Sponsor
- Boryung
- Start
- May 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fimasartan, atorvastatin and ezetimibe in hypertension (HTN) and hypercholesterolemia, sponsored by Boryung. Primary endpoints: Maximum (peak) steady-state plasma drug concentration and Area under the plasma concentration-time curve from time zero to time t. Started May 2022; status: completed.
02
Drugs
fimasartanatorvastatinezetimibe
03
Conditions
hypertension (HTN)hypercholesterolemia
Beyond the preview
Go deeper on NCT05372380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372380.